PolyPid (PYPD) to Release Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is projected to post its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect PolyPid to post earnings of ($0.90) per share for the quarter.

PolyPid Price Performance

Shares of PYPD opened at $2.90 on Friday. The company’s 50-day moving average is $3.05 and its 200-day moving average is $3.34. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. The firm has a market capitalization of $29.55 million, a PE ratio of -0.37 and a beta of 1.32. PolyPid has a fifty-two week low of $2.37 and a fifty-two week high of $7.00.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PYPD. Craig Hallum initiated coverage on PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright decreased their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price for the company.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.